Ginkgo Bioworks Holdings, Inc. (DNA) is a publicly traded Healthcare sector company. As of November 17, 2026, DNA trades at $8.39 with a market cap of $551.01M and a P/E ratio of -2.46. DNA moved -2.12% today. Year to date, DNA is -6.26%; over the trailing twelve months it is +6.88%. Its 52-week range spans $5.00 to $18.22. Analyst consensus is sell with an average price target of $8.00. Rallies surfaces DNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for DNA, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $8.39 |
| Market Cap | $551.01M |
| P/E Ratio | -2.46 |
| EPS | $-5.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.22 |
| 52-Week Low | $5.00 |
| Volume | 2.33M |
| Avg Volume | 0 |
| Revenue (TTM) | $111.86M |
| Net Income | $-290.80M |
| Gross Margin | 0.00% |
2 analysts cover DNA: 0 strong buy, 0 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is sell. Average price target: $8.00.